Increased risk for urological cancer associated with anxiety disorder: a retrospective cohort study. Issue 1 (December 2016)

• Record Type: Journal Article
• Authors: Chen, Yung-Chan; Kao, Li-Ting; Lin, Herng-Ching; Lee, Hsin-Chien; Huang, Chung-Chien; Chung, Shiu-Dong
• Is Part Of: BMC urology. Volume 16:Issue 1(2016)
• Page Start: 1
• Page End: 8
• Publication Date: 2016-12
• Subjects: Anxiety disorder -- Urological cancer -- Bladder cancer -- Epidemiology; Urology -- Periodicals; 616.6005
• DOI: 10.1186/s12894-016-0187-x
• Languages: English
• ISSNs: 1471-2490

Abstract

Abstract Background Anxiety disorders (ADs) are common with a high rate of medical comorbidities. Although the association between ADs and the overall cancer risk remains controversial, patients with ADs were found to be more likely to develop specific cancer types. Herein, we estimated the risk of developing urological cancers among patients with ADs in a 5-year follow-up period using a population-based database. Methods Two study cohorts were identified from the Taiwan Longitudinal Health Insurance Database 2005: patients with ADs, and comparison subjects selected by one-to-one matching for sex, age, and the year of recruitment. Follow-up was undertaken to determine whether sampled patients and comparison subjects had developed urological cancers in the subsequent 5 years. Results We found that urological cancers occurred among 0.54% of patients with ADs and 0.13% of comparison subjects. After adjusting for sociodemographic characteristics, medical comorbidities, and alcohol and tobacco use disorder, the stratified Cox proportional hazard regression suggested that patients with ADs were more likely to develop urological cancers relative to comparison subjects (adjusted hazard ratio, 3.67; 95% confidence interval, 2.85 ~ 4.72). The adjusted HR for males with ADs was 3.82 (95% CI: 2.79 ~ 5.23) in comparison to males without ADs. In addition, the adjusted HR for females with ADs was 3.47 (95% CI: 2.26 ~ 5.31) than those females without ADs. Conclusions We concluded that during the 5-year follow-up period, there was a significantly increased risk of urological cancers among patients with ADs.